迪瑞医疗: 2025年半年度业绩预告

Group 1 - The company expects a net loss of between 22 million and 33 million RMB for the current reporting period, compared to a profit of 165.24 million RMB in the same period last year [1] - The net profit after deducting non-recurring gains and losses is expected to be a loss of between 26 million and 39 million RMB, compared to a profit of 162.36 million RMB in the previous year [1] - The significant decline in net profit is attributed to lower-than-expected installation and reagent volume of the company's instrument products in the domestic market, despite a relatively stable market environment [1][2] Group 2 - The company has communicated with the accounting firm regarding the performance forecast, and there are no significant disagreements regarding the forecast for this reporting period [1] - The company has recognized impairment losses totaling approximately 22.42 million RMB, which has significantly increased compared to the same period last year, impacting the net profit attributable to shareholders [2]